The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict DexCom's revenue will improve 3.2% and EPS will remain in the red.
The average estimate for revenue is $22.1 million. On the bottom line, the average EPS estimate is -$0.20.
Last quarter, DexCom reported revenue of $20.1 million. GAAP reported sales were 42% higher than the prior-year quarter's $14.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at -$0.19. GAAP EPS were -$0.21 for Q1 versus -$0.19 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 46.7%, 1,060 basis points better than the prior-year quarter. Operating margin was -76.6%, 710 basis points better than the prior-year quarter. Net margin was -70.0%, 1,360 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $94.0 million. The average EPS estimate is -$0.71.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 76 members out of 173 rating the stock outperform, and 97 members rating it underperform. Among 62 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 19 give DexCom a green thumbs-up, and 43 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on DexCom is outperform, with an average price target of $12.54.
Over the decades, small-cap stocks like DexCom have provided market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: 2 Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add DexCom to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
This News Explains Why DexCom Is Dropping Today
Shares slide after news breaks that a competitor's product nabs an important reimbursement win.
3 Top Medical Device Stocks to Buy Now
Looking to put money to work in this under-the-radar sector? Here are three top stocks to consider.
5 Top Stocks for October
Looking for a few great stocks to buy this month? Here are five top opportunities for you to consider.